SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
MWN-AI** Summary
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Natera, Inc. (NASDAQ: NTRA) presented compelling results from a large-scale pan-cancer study evaluating the clinical performance of its Signatera Genome assay. Analyzing over 2,600 plasma samples from 392 patients across five cancer types—breast cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and colorectal cancer—the findings demonstrated impressive metrics: an overall sensitivity of 94% and a specificity of 100%. Notably, the assay achieved a longitudinal sensitivity of 100% for both lung and renal cancers, with post-surgical landmark sensitivity exceeding 70% for lung and breast cancers.
Signatera Genome also proved exceptionally sensitive, identifying nearly 50% of cases in the ultra-sensitive detection range of less than 100 parts per million (PPM). The test’s predictive capability was underlined by its ability to identify patients with significantly different long-term outcomes; Signatera-negative patients maintained a remarkable 100% distant relapse-free survival (DRFS) at 12 months, compared to just 41% for Signatera-positive individuals at the same timeframe. Moreover, Signatera detected recurrence an average of three months earlier than another assay, the Signatera Exome.
The study also revealed that Signatera-positive patients benefitting from adjuvant therapy experienced a DRFS of 83%, in contrast to 49% in untreated counterparts, while minimal difference was observed for Signatera-negative patients, underscoring the test’s potential in guiding treatment decisions. Natera's Signatera assay thus demonstrates not only a strong performance in detecting residual disease but also provides critical insights into patient prognosis and tailored therapy, marking a significant advancement in cancer care.
MWN-AI** Analysis
Natera, Inc. (NASDAQ: NTRA) has recently showcased remarkable results for its Signatera Genome assay at the 2025 ASCO Annual Meeting, significantly raising expectations surrounding its market potential. With a pan-cancer sensitivity of 94% and an impressive specificity of 100%, Signatera Genome is positioned as a leader in liquid biopsy diagnostics.
The analytical prowess of the assay, with detection limits down to 1 part per million (PPM), provides clinicians the ability to monitor cancer recurrences with unparalleled accuracy. The data indicating 100% sensitivity in lung and renal cancers, coupled with over 70% post-surgical sensitivity in both lung and breast cancers, suggests a strong potential for early intervention in these patient demographics.
Furthermore, the predictive value of Signatera is compelling; patients who tested negative exhibited a starkly favorable prognosis, showcasing a distant relapse-free survival (DRFS) rate of 100% at 12 months. Conversely, Signatera-positive patients have substantially lower survival rates, indicating a crucial role for this assay in guiding treatment decisions.
The ability to detect recurrences 3 months earlier than traditional methods could represent a significant advancement in personalized cancer care, translating to earlier interventions and potentially better patient outcomes. Notably, the enhanced DRFS rates associated with adjuvant therapy for Signatera-positive patients underscores the test's capability to finely discern which patients may benefit most from additional treatment.
From an investment viewpoint, Natera appears well-positioned for long-term growth, driven by the strategic integration of Signatera in oncological practices. Investors should consider that while the current valuations may reflect positive sentiment, the ongoing clinical validation and regulatory support of the assay will be critical in sustaining momentum.
Overall, Natera's Signatera Genome represents a pivotal advancement in precision oncology, promising to redefine standards of care and patient management in the near future. Stakeholders should closely monitor the firm's progress, regulatory developments, and the expansion of clinical applications to maximize investment opportunities.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study analyzed the performance of Signatera Genome in a cohort of 392 patients (> 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and colorectal cancer). Key results included:
- Excellent pan-cancer performance : Signatera Genome demonstrated overall longitudinal sensitivity of 94% and specificity of 100% across 5 cancer types. Longitudinal sensitivity was 100% in lung cancer and renal cancer, and post-surgical landmark sensitivity was over 70% in both lung cancer and breast cancer.
- Ultrasensitive detection: In the surveillance setting, nearly 50% of Signatera-positive cases were detected in the ultra-sensitive range (?100 parts per million).
- Highly predictive of long-term outcomes: In the pancancer cohort, patients who tested Signatera-negative had excellent prognosis, with 100% distant relapse-free survival (DRFS) at 12 months and 99% at 24 months. In contrast, Signatera-positive patients faced a markedly higher risk of recurrence, with DRFS dropping to 41% at 12 months and just 14% at 24 months.
- Extended lead times: Signatera Genome detected recurrence 3 months earlier, on average, compared to the Signatera Exome assay.
- Demonstrates Signatera’s potential to identify which patients may benefit from adjuvant therapy : Among Signatera-positive patients, those who received adjuvant therapy had significantly improved outcomes, with a 12-month DRFS of 83% compared to 49% for those who did not receive therapy. For Signatera-negative patients, there was no meaningful benefit from adjuvant therapy with a 12-month DRFS of 93% (treated) vs. 98% (observation).
“These results highlight that our ultra-sensitive Signatera Genome assay not only enables detection of ctDNA at extremely low levels, but also provides powerful insights into patient prognosis and treatment response,” said Alexey Aleshin, M.D., MBA, corporate chief medical officer and general manager of oncology at Natera. “This is one of the largest MRD studies of a genome tumor-informed MRD assay, and reinforces the excellent performance of Signatera across a wide range of solid tumors.”
About Signatera
Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com .
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602831213/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
FAQ**
How does the overall pan-cancer sensitivity of 94% and specificity of 100% for Natera Inc. (NASDAQ: NTRA) affect the commercial potential of the Signatera Genome assay in oncology diagnostics?
With the ability to detect cancer recurrence 3 months earlier on average, how might the Signatera Genome assay by Natera Inc. (NTRA) impact treatment strategies for oncology patients?
Considering the findings that Signatera-positive patients show markedly lower distant relapse-free survival at 12 and 24 months, what implications does this have for the adoption of Natera Inc.'s (NASDAQ: NTRA) test in clinical settings?
How might the ultra-sensitive range detection capabilities of Signatera Genome influence patient management in cancer care, and what role does Natera Inc. (NTRA) envision in personalized medicine moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Natera Inc. (NASDAQ: NTRA).
NASDAQ: NTRA
NTRA Trading
4.76% G/L:
$197.42 Last:
483,779 Volume:
$193.73 Open:
